semaglutide adolescent obesity trial 2022 Wegovy approved to help teens with lose weight Effect of semaglutide 2.4 mg

Retatrutide 20 mg: GLP-1/GIP/glucagon triple agonist for weight loss and metabolic regulation

The makers of Ozempic and Mounjaro, drugs used for both weight loss and diabetes management, are facing a lawsuit claiming the medications can cause "stomach paralysis." Janet Shamlian reports.

Men were excluded if they had a prior erectile dysfunction diagnosis, any phosphodiesterase-5 inhibitors prescription, intracavernosal injections, penile prosthesis placement, history of testosterone deficiency, testosterone prescription, pelvic radiation, radical prostatectomy, pulmonary hypertension, or were deceased

GLP-1 receptor agonists like semaglutide are approved for adults 18 and older, though clinical guidelines suggest careful evaluation based on individual health status and weight loss goals

I spoke to Dr

However, this information is for educational purposes only and should not replace professional medical advice